STOCKHOLM, April 29, 2020 /PRNewswire/ -- Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company's interim report for the period January - March 2020 on Thursday, May 7, 2020 at 07:30 a.m. CET.
Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on May 7, 2020, at 13:00 - 14:00 p.m CET.
Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Q1 interim report followed by a Q&A-session.To participate, please call any of the following phone numbers from:
The information was submitted for publication, through the agency of the contact person set out above, at 13:00 CET on April 29, 2020.
Q-linea is an infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea's vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.
For more information, please contact:
CFO, Q-linea AB
This information was brought to you by Cision http://news.cision.com
The following files are available for download: